Evidence map›Paper›PMID 36401337›Full record

ArticleJournal of cachexia, sarcopenia and muscle2023

Capsaicin alleviates cisplatin-induced muscle loss and atrophy in vitro and in vivo.

Ko-Chieh Huang, Yi-Fen Chiang, Tsui-Chin Huang, Hsin-Yuan Chen, Po-Han Lin, Mohamed Ali, Shih-Min Hsia

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ko-Chieh HuangSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan.
Yi-Fen ChiangSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan.
Tsui-Chin HuangGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Hsin-Yuan ChenSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan.
Po-Han LinSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan.
Mohamed AliClinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Shih-Min HsiaSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0003-2888-2618
Taipei Medical University · TWAin Shams University · EGNational Yang Ming Chiao Tung University · TWTaipei Medical University Hospital · TW

Funding

Ministry of Science and Technology MOST109-2314-B-038-059Ministry of Science and Technology MOST109-2628-B-038-015Ministry of Science and Technology MOST110-2314-B-038-158Ministry of Science and Technology MOST110-2628-B-038-018Ministry of Science and Technology MOST110-2811-B-038-543National Science and Technology Council NSTC111-2314-B-038-006National Science and Technology Council NSTC111-2628-B-038-019National Science and Technology Council NSTC111-2811-B-038-022
6 · The paper itself

Abstract

backgroundCisplatin (CP) is a widely used chemotherapeutic drug with subsequent adverse effects on different organs and tissues including skeletal muscle loss and atrophy as the most common clinical symptoms. The molecular mechanism of cisplatin-induced muscle atrophy is not clearly understood. However, recent significant advances indicate that it is related to an imbalance in both the protein status and apoptosis. Capsaicin (CAP) is one of the major ingredients in chilli peppers. It is a valuable pharmacological agent with several therapeutic applications in controlling pain and inflammation with particular therapeutic potential in muscle atrophy. However, the mechanisms underlying its protective effects against cisplatin-induced muscle loss and atrophy remain largely unknown. This study aims to investigate capsaicin's beneficial effects on cisplatin-induced muscle loss and atrophy in vitro and in vivo.

methodsThe anti-muscle-atrophic effect of capsaicin on cisplatin-induced muscle loss was investigated using in vivo and in vitro studies. By using the pretreatment model, pretreated capsaicin for 24 h and treated with cisplatin for 48 h, we utilized a C

resultsOur study results indicated that cisplatin caused lower cell viability and showed a subset of hallmark signs typically recognized during atrophy, including severe reduction in the myotube diameter, repression of Akt, and mTOR protein expression. However, pretreatment with capsaicin could ameliorate cisplatin-induced muscle atrophy by up-regulating the protein synthesis in skeletal muscle as well as down-regulating the markers of protein degradation. Additionally, capsaicin was able to downregulate the protein expression of apoptosis-related markers, activated TRPV1 and autophagy progress modulation and the recovery of lysosome function. In vivo, capsaicin could relieve oxidative stress and cytokine secretion while modulating autophagy-related lysosome fusion, improving grip strength, and alleviating cisplatin-induced body weight loss and gastrocnemius atrophy.

conclusionsThese findings suggest that capsaicin can restore cisplatin-induced imbalance between protein synthesis and protein degradation pathways and it may have protective effects against cisplatin-induced muscle atrophy.

Indexed as

CapsaicinCisplatinMuscle, SkeletalMuscular AtrophyAnimalsMiceMice, Inbred C57BLCapsaicinCisplatinCapsaicinCisplatinMuscle atrophyMyotube

Identifiers

PMID36401337
PMCPMC9891949
OpenAlexW4309410574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.